AUTL241220P2500
- 0.25
- 0.000.00%
Autolus Therapeutics Newsroom
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Express News | Reported Earlier, Autolus Therapeutics Revealed New Data Supporting Obe-cel's Clinical And Economic Benefits At ASH 2024
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
Autolus Therapeutics: Undervalued Potential in ALL Treatment With Obe-cel
Autolus Therapeutics Plc (AUTL): A Bull Case Theory
Positive Outlook for Autolus Therapeutics Driven by Regulatory Approval and Competitive Positioning in CAR-T Therapy
Needham Maintains Autolus Therapeutics(AUTL.US) With Buy Rating, Maintains Target Price $10
Autolus Therapeutics Announces Publication of Data From the FELIX Study of Obe-cel in R/r Adult B-ALL Patients in The New England Journal of Medicine
Is Autolus Therapeutics (NASDAQ:AUTL) Using Too Much Debt?
European Equities Traded in the US as American Depositary Decline in Tuesday Trading
Goldman Sachs Upgrades Autolus Therapeutics(AUTL.US) to Buy Rating, Raises Target Price to $7.6
Autolus Therapeutics Analyst Ratings
Goldman Sachs Upgrades Autolus Therapeutics to Buy From Neutral, Adjusts Price Target to $7.60 From $7
Autolus Therapeutics: FDA Approval of Aucatzyl De-Risks Platform, Significant Upside Anticipated
This InterContinental Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Redburn Atlantic Initiates Autolus Therapeutics(AUTL.US) With Buy Rating, Announces Target Price $13
Autolus Therapeutics Upgraded to Buy From Neutral at Redburn Atlantic
Express News | Needham Reiterates Buy on Autolus Therapeutics, Maintains $10 Price Target
A Quick Look at Today's Ratings for Autolus Therapeutics(AUTL.US), With a Forecast Between $8 to $13
Autolus Therapeutics | 10-Q: Q3 2024 Earnings Report